<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3426">
  <stage>Registered</stage>
  <submitdate>5/01/2012</submitdate>
  <approvaldate>5/01/2012</approvaldate>
  <nctid>NCT01507077</nctid>
  <trial_identification>
    <studytitle>ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity</studytitle>
    <scientifictitle>ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ZAF-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ZGN-440
Treatment: drugs - ZGN-440 sterile diluent

Placebo Comparator: ZGN-440 sterile diluent - 

Experimental: ZGN-440 - 


Treatment: drugs: ZGN-440
Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

Treatment: drugs: ZGN-440 sterile diluent
Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Demonstrate safe doses of ZGN-440 for reduction of body weight in obese female volunteers. - Measures of the safety and tolerability of ZGN-440 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests.</outcome>
      <timepoint>Approximately 4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence, severity and dose-relationship of adverse events as well as changes in physical examinations, ECGs, vital signs and/or laboratory evaluations as a measure of safety and tolerability.</outcome>
      <timepoint>Approximately 4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak plasma concentration of ZGN-440 to assess relationship to weight loss.</outcome>
      <timepoint>Approximately 4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Elimination half-life of ZGN-440 to assess relationship to weight loss.</outcome>
      <timepoint>Approximately 4 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Obese but otherwise healthy females

          -  Non-childbearing potential (surgically sterile, post-menopausal, or receiving
             implanted or injectable contraceptive for at least 3 months)

          -  BMI = 30 and = 45 kg/m2

          -  Stable body weight during the past 2 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of weight loss agents in the past month

          -  History of eating disorder

          -  History of type 1 or type 2 diabetes mellitus

          -  Current smokers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Q-Pharm Clinics, Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <postcode> - Brisbane</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Zafgen, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety,
      and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01507077</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>J K Marjason, MD</name>
      <address>Q-Pharm Clinics, Royal Brisbane and Women's Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>